,
Dexamethasone with Transplantation for Myeloma, N Engl J Med. 6 avr, vol.376, issue.14, pp.1311-1331, 2017. ,
, The New England Journal of Medicine, vol.14, 2004.
Multiple Myeloma. n engl j med, vol.15, 2011. ,
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From, Journal of Clinical Oncology. 20 mai, vol.25, issue.15, pp.1993-2002, 1973. ,
, Cancer Statistics Review, 1975.
Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012: étude à partir des registres des cancers du réseau Francim, 2013. ,
International Staging System for Multiple Myeloma, Journal of Clinical Oncology. 20 mai, vol.23, issue.15, pp.3412-3432, 2005. ,
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, vol.15, pp.538-586, 2014. ,
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood. 12 mai, vol.117, pp.5019-5051, 2011. ,
, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, The International Myeloma Working Group, vol.121, pp.749-57, 2003.
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, JCO. 10 sept, vol.33, issue.26, pp.2863-2872, 2015. ,
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?, Blood. 17 déc, vol.126, issue.25, pp.2713-2722, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01813432
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients, Leukemia. mars, vol.28, issue.3, pp.675-684, 2014. ,
Play a Major Role in Defining Long-Term Survival, Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities, vol.30, pp.1949-52, 2012. ,
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, vol.15, pp.538-586, 2014. ,
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine. 21 févr, vol.346, issue.8, pp.564-573, 2002. ,
Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis, Leukemia, vol.23, issue.10, pp.1691-1698, 2009. ,
A monoclonal gammopathy precedes multiple myeloma in most patients, Blood. 28 mai, vol.113, issue.22, pp.5418-5440, 2009. ,
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey, Leukemia. juill, vol.28, issue.7, pp.1537-1579, 2014. ,
Nordic Myeloma Study Group and British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005, British Journal of Haematology. févr, vol.132, issue.4, pp.410-51, 2006. ,
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia. janv, vol.23, issue.1, pp.3-9, 2009. ,
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study, The Lancet. mai, vol.375, issue.9727, pp.1721-1729, 2010. ,
Plasma cell leukemia: from biology to treatment, European Journal of Haematology. juill, vol.95, issue.1, pp.16-26, 2015. ,
Plasma cell leukemia: update on biology and therapy, Leukemia & Lymphoma. 3 juill, vol.58, issue.7, pp.1538-1585, 2017. ,
Update on diagnosis, risk stratification, and management: DISPENZIERI, American Journal of Hematology. août, vol.92, issue.8, pp.814-843, 2017. ,
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma, Blood. 21 août, vol.124, issue.8, pp.1300-1303, 2014. ,
Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study, The Lancet Oncology. août, vol.15, issue.9, pp.931-973, 2014. ,
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia. juin, vol.24, issue.6, pp.1121-1128, 2010. ,
The Treatment of Multiple Myeloma, New England Journal of Medicine. 17 févr, vol.330, issue.7, pp.484-493, 1994. ,
Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO), Journal of Cancer Research and Clinical Oncology. avr, vol.132, issue.4, pp.205-217, 2006. ,
Primary Dexamethasone Treatment of Multiple Myeloma, vol.5, 1992. ,
Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma, N Engl J Med. 11 juill, vol.335, issue.2, pp.91-98, 1996. ,
Mechanism of action of lenalidomide in hematological malignancies, J Hematol Oncol, vol.2, issue.1, p.36, 2009. ,
Continuous cultures of fused cells secreting antibody of predefined specificity, Nature. août, vol.256, issue.5517, pp.495-502, 1975. ,
Disponible sur, 2019. ,
, New England Journal of Medicine. 25 août, vol.375, issue.8, pp.754-66, 2016.
,
, New England Journal of Medicine, vol.375, issue.14, pp.1319-1350, 2016.
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design, Future Oncology. mai, vol.14, issue.11, pp.1035-1082, 2018. ,
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM, Blood. 9 juin, vol.127, issue.23, pp.2833-2873, 2016. ,
The Basic Principles of Chimeric Antigen Receptor Design, Cancer Discovery. avr, vol.3, issue.4, pp.388-98, 2013. ,
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors, Nat Rev Clin Oncol. mai, vol.10, issue.5, pp.267-76, 2013. ,
,
, B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma, Journal of Clinical Investigation. 29 avr, vol.129, issue.6, pp.2210-2231, 2019.
,
, Thalidomide : mécanismes d'action et indications en hématologie. La Revue de Médecine Interne, févr, vol.26, issue.2, pp.119-146, 2005.
,
, Rev Med Interne. sept, vol.36, issue.9, pp.613-621, 2015.
The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents, vol.10, 2003. ,
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma, The New England Journal of Medicine, vol.12, 2005. ,
Targeting the proteasome as a therapeutic strategy against haematological malignancies, Expert Opinion on Investigational Drugs. févr, vol.15, issue.2, pp.117-147, 2006. ,
, Commission de la Transparence, KYPROLIS [Internet], HAS, 2018.
,
, New England Journal of Medicine. 8 janv, vol.372, issue.2, pp.142-52, 2015.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma, New England Journal of Medicine. 28 avr, vol.374, issue.17, pp.1621-1655, 2016. ,
Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor, British Journal of Cancer. déc, vol.95, issue.S1, pp.2-6, 2006. ,
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet Oncology, vol.14, pp.1129-1169, 2013. ,
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. The Lancet Oncology, vol.15, pp.1195-206, 2014. ,
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma, Blood, vol.122, issue.14, pp.2331-2338, 2013. ,
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study, The Lancet Oncology. mars, vol.12, issue.3, pp.263-72, 2011. ,
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial, The Lancet. déc, vol.376, issue.9757, pp.1989-99, 2010. ,
,
Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma, JCO. 20 mars, vol.29, issue.9, p.26, 2011. ,
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression, Haematologica. 1 avr, vol.93, issue.4, pp.560-565, 2008. ,
International uniform response criteria for multiple myeloma, Leukemia. sept, vol.20, issue.9, pp.1467-73, 2006. ,
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, The Lancet Oncology. août, vol.17, issue.8, pp.328-374, 2016. ,
,
, Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation, Blood, vol.15, issue.10, pp.4017-4040, 2008.
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma, Blood. 6 déc, vol.132, issue.23, pp.2456-64, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02006039
Hallmarks of Cancer: The Next Generation, Cell. mars, vol.144, issue.5, pp.646-74, 2011. ,
Osteogenesis in transplants of bone marrow cells, p.15 ,
,
, Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues: Cloning In Vitro and Retransplantation In Vivo, Transplantation. avr, vol.17, issue.4, pp.641-50, 1974.
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, vol.8, issue.4, pp.315-322, 2006. ,
Fat tissue: an underappreciated source of stem cells for biotechnology, Trends in Biotechnology. avr, vol.24, issue.4, pp.150-154, 2006. ,
Peripheral Blood-Derived Mesenchymal Stem Cells: Candidate Cells Responsible for Healing Critical-Sized Calvarial Bone Defects: Blood-Derived MSCs in Calvarial Bone Healing, STEM CELLS Translational Medicine. avr, vol.4, issue.4, pp.359-68, 2015. ,
Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC, Cell Commun Signal. déc, vol.9, issue.1, p.12, 2011. ,
Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord, Sci Rep. déc, vol.8, issue.1, p.5014, 2018. ,
Bone-marrow haematopoietic-stem-cell niches, Nat Rev Immunol. févr, vol.6, issue.2, pp.93-106, 2006. ,
MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2, Blood. 25 juin, vol.113, issue.26, pp.392-402, 2009. ,
Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide, Cell Stem Cell. févr, vol.2, issue.2, pp.141-50, 2008. ,
Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages, Cancer Letters. déc, vol.326, issue.1, pp.59-68, 2012. ,
Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors, Journal of Molecular Cell Biology. 3 sept, p.90, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02390801
CD54-Mediated Interaction with Pro-inflammatory Macrophages Increases the Immunosuppressive Function of Human Mesenchymal Stromal Cells, Stem Cell Reports. avr, vol.8, issue.4, pp.961-76, 2017. ,
Safety and Complications Reporting Update on the Re-Implantation of Culture-Expanded Mesenchymal Stem Cells Using Autologous Platelet Lysate Technique, CSCR. 1 déc, vol.6, issue.4, pp.368-78, 2011. ,
Treatment of Osteonecrosis of the Femoral Head with Implantation of Autologous Bone-Marrow Cells: A Pilot Study, The Journal of Bone and Joint Surgery-American, vol.86, issue.6, pp.1153-60, 2004. ,
Safety of intraarticular cell-therapy with culture-expanded stem cells in humans: a systematic literature review. Osteoarthritis and Cartilage, vol.21, pp.1465-73, 2013. ,
Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial, Transplantation. août, vol.99, issue.8, pp.1681-90, 2015. ,
Comparison of Allogeneic vs Autologous Bone Marrow-Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy: The POSEIDON Randomized Trial, JAMA. 12 déc, vol.308, issue.22, p.2369, 2012. ,
Bilateral Transplantation of Allogenic Adult Human Bone Marrow-Derived Mesenchymal Stem Cells into the Subventricular Zone of Parkinson's Disease: A Pilot Clinical Study, Stem Cells International, vol.10, issue.1, pp.1-12, 2012. ,
Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graftversus-Host Disease, Biology of Blood and Marrow Transplantation. juill, vol.15, issue.7, pp.804-815, 2009. ,
A Peculiar Molecular Profile of Umbilical Cord-Mesenchymal Stromal Cells Drives Their Inhibitory Effects on Multiple Myeloma Cell Growth and Tumor Progression, Stem Cells and Development. 15 juin, vol.24, issue.12, pp.1457-70, 2015. ,
Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent Imaging. Stem Cells, vol.27, pp.2614-2637, 2009. ,
CCR2-Dependent Recruitment of Macrophages by Tumor-Educated Mesenchymal Stromal Cells Promotes Tumor Development and Is Mimicked by TNF?, Cell Stem Cell. déc, vol.11, issue.6, pp.812-836, 2012. ,
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells, Gene Ther. mai, vol.15, issue.10, pp.730-738, 2008. ,
Mesenchymal Stem Cells Directly Interact with Breast Cancer Cells and Promote Tumor Cell Growth In Vitro and In Vivo, Stem Cells and Development. déc, vol.22, issue.23, pp.3114-3141, 2013. ,
From developmental disorder to heritable cancer: it's all in the BMP/TGF-? family, Nat Rev Genet, vol.4, issue.10, pp.763-73, 2003. ,
Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients, p.12 ,
Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma, Leukemia. janv, vol.21, issue.1, pp.158-63, 2007. ,
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma, Leukemia. mai, vol.21, issue.5, pp.1079-88, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00270565
Mesenchymal stem cell abnormalities in patients with multiple myeloma, Leukemia & Lymphoma. janv, vol.48, issue.10, pp.2032-2073, 2007. ,
A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of DKK1 and Interleukin-6: A Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple Myeloma, STEM CELLS. avr, vol.24, issue.4, pp.986-91, 2006. ,
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget [Internet]. 30 sept, vol.5, 2014. ,
Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma, Cancer Research. 15 mars, vol.72, issue.6, pp.1395-406, 2012. ,
Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors, Leukemia. août, vol.23, issue.8, pp.1515-1542, 2009. ,
Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells. Covas DT, éditeur, PLoS ONE. 21 mars, vol.8, issue.3, p.59756, 2013. ,
,
, Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC), Oncotarget, vol.27, issue.2016
, Disponible sur
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells, Arch Immunol Ther Exp. juin, vol.56, issue.3, pp.207-228, 2008. ,
Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma, Leukemia. févr, vol.31, issue.2, pp.373-81, 2017. ,
Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells, Leukemia Research, vol.34, issue.10, pp.1325-1334, 2010. ,
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression, J Clin Invest. 1 avr, vol.123, issue.4, pp.1542-55, 2013. ,
Anti-?4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis, Blood, vol.104, issue.7, pp.2149-54, 2004. ,
Impairment in Immunomodulatory Function of Mesenchymal Stem Cells from Multiple Myeloma Patients. Archives of Medical Research, vol.41, pp.623-656, 2010. ,
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide, International Journal of Oncology. sept, vol.41, issue.3, pp.876-84, 2012. ,
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma: Serum DKK-1 correlates with myeloma bone disease, European Journal of Haematology. juin, vol.80, issue.6, pp.490-494, 2008. ,
,
, Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation, Molecular Endocrinology. 1 févr, vol.21, issue.2, pp.486-98, 2007.
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma, N Engl J Med. 25 déc, vol.349, issue.26, pp.2483-94, 2003. ,
The role of Dickkopf-1 in bone development, homeostasis, and disease, Blood. 15 janv, vol.113, issue.3, pp.517-542, 2009. ,
The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis, Journal of Cell Science. 15 juin, vol.119, issue.12, pp.2613-2633, 2006. ,
,
Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression, J Biol Chem. 30 sept, vol.280, issue.39, pp.33132-33172, 2005. ,
Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice, J Thromb Haemost, vol.12, issue.10, pp.1706-1722, 2014. ,
Revisiting the biological roles of PAI2 (SERPINB2) in cancer, Nature Reviews Cancer. juill, vol.8, issue.7, pp.535-580, 2008. ,
Fibrinolytic activity in multiple myeloma, Am J Hematol. déc, vol.74, issue.4, pp.231-238, 2003. ,